SCHEMBL7990728

SCHEMBL7990728

CCS(=O)(=O)NC(=O)c1ccc(C)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
ALDH1A1 P00352 7/20 0.55
GAA P10253 3/20 0.55
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
PTGS2 P35354 2/20 0.50
LMNA P02545 3/20 0.49
POLB P06746 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
NOD2 Q9HC29 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680592 0.90 MMP13 (0.61) HDAC1HDAC6ALDH1A1GAANPC1
SCHEMBL7984813 0.87 HDAC1 (0.53) HDAC1HDAC6ALDH1A1GAANPC1
SCHEMBL24052290 0.85 HDAC8 (0.59) HDAC6LMNASMN1; SMN2HTT
SCHEMBL7987132 0.83 ALDH1A1 (0.50) HDAC1ALDH1A1GAARAB9APTGS2
SCHEMBL7984827 0.83 FLT1 (0.61) HDAC1ALDH1A1GAANPC1PTGS2
SCHEMBL7990884 0.83 OGG1 (0.55) HDAC1HDAC6ALDH1A1NPC1RAB9A
SCHEMBL24052028 0.83 PARP10 (0.46) HDAC6ALDH1A1NPC1RAB9ALMNA
SCHEMBL24420690 0.83 LMNA (0.51) HDAC1HDAC6ALDH1A1GAANPC1
SCHEMBL7987067 0.83 PLK1 (0.61) HDAC6ALDH1A1GAANPC1RAB9A
SCHEMBL1370670 0.82 LMNA (0.54) HDAC1HDAC6ALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118647372-A Liquid resin extended release oral naltrexone formulations for the treatment of autism related disorders 阿达瓦克治疗公司 2024-09-13 CN disclosed
US-6331628-B1 REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-18 US disclosed